Join our daily newsletter At The Bell to receive exclusive market insights
- AVITA Medical (AVH) reports its preclinical data establishes proof of concept in two key areas of cell-based gene therapy – skin rejuvenation and epidermolysis bullosa
- Data shows successful regeneration of the skin when AVITA’s Spray-On Skin Cells was paired with the Houston Methodist Research Institute’s (HMRI) patented RNA technologies to reverse cellular aging
- The company says these initial results are a meaningful step forward in the advancement of its epidermolysis bullosa program
- AVITA Medical last traded at $3.21 on January 6
AVITA Medical (AVH) has established a proof of concept for novel treatments using genetically modified skin cells.
Data showed successful regeneration of the skin when AVITA’s Spray-On Skin Cells was paired with the Houston Methodist Research Institute’s (HMRI) patented RNA technologies to reverse cellular aging.
Preclinical results showed the treatment could regenerate skin from gene-modified skin cells to correct the mutation associated with recessive dystrophic epidermolysis bullosa, a rare and incurable skin disorder caused by mutations in the gene encoding structural proteins, resulting in skin fragility and blistering. Epidermolysis bullosa can lead to chronic wounds and an increased risk of squamous cell carcinoma or death.
Dr. Mike Perry, Chief Executive Officer of AVITA Medical, said the company was pleased to partner with leading scientists to explore opportunities for Spray-On Skin Cells in new and broad applications such as skin rejuvenation and genetic skin defects.
“These data, while early, demonstrate promise for skin regeneration from modified Spray-On Skin Cells, for treatment of aging skin with reverse-aged skin cells and for treatment of epidermolysis bullosa with gene-corrected skin cells,” said Dr Perry.
“These initial results are a meaningful step forward in the advancement of our epidermolysis bullosa program,” said Director of the Gates Center for Regenerative Medicine, Dr. Dennis Roop.
AVITA Medical today also announced that it had completed enrollment into its pivotal trial for the use of the RECELL System for soft tissue reconstruction.
Currently, the RECELL System is indicated in the U.S. for treatment of acute thermal burns. With FDA approval, the company expects to expand the use of RECELL to include all acute wounds.
AVITA Medical last traded at $3.21 on January 6.
